715 related articles for article (PubMed ID: 32562915)
1. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
Contini C; Enrica Gallenga C; Neri G; Maritati M; Conti P
Med Hypotheses; 2020 Nov; 144():109876. PubMed ID: 32562915
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Trials; 2020 May; 21(1):422. PubMed ID: 32448345
[TBL] [Abstract][Full Text] [Related]
3. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.
Yang CJ; Wei YJ; Chang HL; Chang PY; Tsai CC; Chen YH; Hsueh PR
J Microbiol Immunol Infect; 2021 Feb; 54(1):27-36. PubMed ID: 33060041
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
5. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
6. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Atluri S; Manchikanti L; Hirsch JA
Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2.
Williamson BN; Pérez-Pérez L; Schwarz B; Feldmann F; Holbrook MG; Singh M; Lye DS; Babusis D; Subramanian R; Haddock E; Okumura A; Hanley PW; Lovaglio J; Bosio CM; Porter DP; Cihlar T; Mackman RL; Saturday G; de Wit E
Antiviral Res; 2022 Feb; 198():105246. PubMed ID: 35032523
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
Elife; 2021 Oct; 10():. PubMed ID: 34617885
[TBL] [Abstract][Full Text] [Related]
11. Case report study of the first five COVID-19 patients treated with remdesivir in France.
Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 Is a Multifaceted Challenging Pandemic Which Needs Urgent Public Health Interventions.
Contini C; Caselli E; Martini F; Maritati M; Torreggiani E; Seraceni S; Vesce F; Perri P; Rizzo L; Tognon M
Microorganisms; 2020 Aug; 8(8):. PubMed ID: 32806657
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
[TBL] [Abstract][Full Text] [Related]
15. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
17. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient.
Hillaker E; Belfer JJ; Bondici A; Murad H; Dumkow LE
Pharmacotherapy; 2020 Jun; 40(6):592-598. PubMed ID: 32281114
[TBL] [Abstract][Full Text] [Related]
18. [Remdesivir for COVID-19].
Fujita Y
Nihon Yakurigaku Zasshi; 2022; 157(1):31-37. PubMed ID: 34980809
[TBL] [Abstract][Full Text] [Related]
19. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
